HK1187540A1 - 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物 - Google Patents

用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物

Info

Publication number
HK1187540A1
HK1187540A1 HK14100670.1A HK14100670A HK1187540A1 HK 1187540 A1 HK1187540 A1 HK 1187540A1 HK 14100670 A HK14100670 A HK 14100670A HK 1187540 A1 HK1187540 A1 HK 1187540A1
Authority
HK
Hong Kong
Prior art keywords
methylaminophenoxy
pyrdin
treating cancer
benzamide derivatives
benzamide
Prior art date
Application number
HK14100670.1A
Other languages
English (en)
Inventor
Takashi Nakagawa
Makoto Sakamoto
Kazuya Yamaguchi
Yuki Terauchi
Masamichi Shirakura
Yasuo Harada
Yutaka Kojima
Takumi Sumida
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1187540A1 publication Critical patent/HK1187540A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK14100670.1A 2010-10-04 2014-01-22 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物 HK1187540A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38939310P 2010-10-04 2010-10-04
PCT/JP2011/073165 WO2012046825A1 (en) 2010-10-04 2011-10-03 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer

Publications (1)

Publication Number Publication Date
HK1187540A1 true HK1187540A1 (zh) 2014-04-11

Family

ID=44872549

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14100670.1A HK1187540A1 (zh) 2010-10-04 2014-01-22 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物

Country Status (29)

Country Link
US (7) US8946437B2 (zh)
EP (1) EP2624833B1 (zh)
JP (1) JP5715690B2 (zh)
KR (1) KR101797797B1 (zh)
CN (1) CN103189061B (zh)
AR (1) AR083287A1 (zh)
AU (1) AU2011313236B2 (zh)
BR (1) BR112013007841B1 (zh)
CA (1) CA2813153C (zh)
CO (1) CO6660459A2 (zh)
DK (1) DK2624833T3 (zh)
EA (1) EA021627B1 (zh)
ES (1) ES2526574T3 (zh)
HK (1) HK1187540A1 (zh)
HR (1) HRP20141237T1 (zh)
IL (1) IL225520A (zh)
MX (1) MX2013003589A (zh)
MY (1) MY157563A (zh)
NZ (1) NZ609151A (zh)
PL (1) PL2624833T3 (zh)
PT (1) PT2624833E (zh)
RS (1) RS53749B1 (zh)
SG (1) SG189146A1 (zh)
SI (1) SI2624833T1 (zh)
SM (1) SMT201500056B (zh)
TW (1) TWI526431B (zh)
UA (1) UA110037C2 (zh)
WO (1) WO2012046825A1 (zh)
ZA (1) ZA201302332B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083287A1 (es) * 2010-10-04 2013-02-13 Otsuka Pharma Co Ltd Derivados de fenoxi-piridin-3-il-benzamida
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
JP2022525268A (ja) 2019-03-25 2022-05-12 大塚製薬株式会社 抗腫瘍組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
EP1773797A2 (en) 2004-08-06 2007-04-18 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
ES2463450T3 (es) * 2005-12-05 2014-05-28 Otsuka Pharmaceutical Co., Ltd. Fármaco medicinal
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
AR083287A1 (es) * 2010-10-04 2013-02-13 Otsuka Pharma Co Ltd Derivados de fenoxi-piridin-3-il-benzamida
JP2022525268A (ja) * 2019-03-25 2022-05-12 大塚製薬株式会社 抗腫瘍組成物

Also Published As

Publication number Publication date
MY157563A (en) 2016-06-30
NZ609151A (en) 2015-01-30
EA021627B1 (ru) 2015-07-30
HRP20141237T1 (hr) 2015-02-13
SMT201500056B (it) 2015-05-05
US20200031773A1 (en) 2020-01-30
UA110037C2 (uk) 2015-11-10
EA201390323A1 (ru) 2013-09-30
RS53749B1 (en) 2015-06-30
MX2013003589A (es) 2013-06-24
CN103189061A (zh) 2013-07-03
SI2624833T1 (sl) 2015-03-31
BR112013007841A2 (pt) 2016-06-07
CA2813153C (en) 2019-01-15
WO2012046825A1 (en) 2012-04-12
PL2624833T3 (pl) 2015-05-29
KR101797797B1 (ko) 2017-11-14
TW201307289A (zh) 2013-02-16
JP2013538785A (ja) 2013-10-17
US20230139808A1 (en) 2023-05-04
US20130267565A1 (en) 2013-10-10
US20170298023A1 (en) 2017-10-19
US8946437B2 (en) 2015-02-03
IL225520A0 (en) 2013-06-27
CA2813153A1 (en) 2012-04-12
EP2624833B1 (en) 2014-12-10
US20210017134A1 (en) 2021-01-21
ES2526574T3 (es) 2015-01-13
CO6660459A2 (es) 2013-04-30
IL225520A (en) 2016-05-31
DK2624833T3 (en) 2015-01-05
KR20130121826A (ko) 2013-11-06
BR112013007841B1 (pt) 2020-03-03
AU2011313236B2 (en) 2016-05-19
SG189146A1 (en) 2013-05-31
AR083287A1 (es) 2013-02-13
PT2624833E (pt) 2014-12-26
US20150105432A1 (en) 2015-04-16
US20180265471A1 (en) 2018-09-20
AU2011313236A1 (en) 2013-04-18
CN103189061B (zh) 2015-09-02
TWI526431B (zh) 2016-03-21
JP5715690B2 (ja) 2015-05-13
ZA201302332B (en) 2014-07-30
EP2624833A1 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
HK1252832A1 (zh) 用於治療結腸直腸癌的方法
HK1200363A1 (zh) 用於治療癌症的化合物
EP2542081A4 (en) COMPOSITIONS FOR CANCER TREATMENT
EP2542584B8 (en) Methods for treating pancreatic cancer
PT3412687T (pt) Métodos de tratamento de dlbcl
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
ZA201203449B (en) Sulfoxide derivatives for treating tumors
IL225623A0 (en) Psoriasis treatment methods
IL222958A0 (en) Cancer treatment
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
IL228644A0 (en) Cancer treatment methods
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
HK1247207A1 (zh) 可治療癌症和其他疾病的新化合物
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
HK1187540A1 (zh) 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物
EP2563353A4 (en) COMPOUNDS FOR ANTIFUNGAL TREATMENT
GB201019034D0 (en) Treatment for tumors
GB0914322D0 (en) Compounds for treating cancer
AU2012901918A0 (en) Methods for treating cancer
GB201301168D0 (en) Cancer treatment